A proteomic atlas of the neointima identifies novel druggable targets for preventive therapy

Michael Wierer, Julia Werner, Jana Wobst, Adnan Kastrati, Ganildo Cepele, Redouane Aherrahrou, Hendrik B. Sager, Jeanette Erdmann, Martin Dichgans, Veit Flockerzi, Mete Civelek, Alexander Dietrich, Matthias Mann*, Heribert Schunkert, Thorsten Kessler

*Corresponding author for this work
2 Citations (Scopus)


Aims In-stent restenosis is a complication after coronary stenting associated with morbidity and mortality. Here, we sought to investigate the molecular processes underlying neointima formation and to identify new treatment and prevention targets. Methods Neointima formation was induced by wire injury in mouse femoral arteries. High-accuracy proteomic measurement and results of single femoral arteries to a depth of about 5000 proteins revealed massive proteome remodelling, with more than half of all proteins exhibiting expression differences between injured and non-injured vessels. We observed major changes in the composition of the extracellular matrix and cell migration processes. Among the latter, we identified the classical transient receptor potential channel 6 (TRPC6) to drive neointima formation. While Trpc6-/mice presented reduced neointima formation compared to wild-type mice (1.44 ± 0.39 vs. 2.16 ± 0.48, P = 0.01), activating or repressing TRPC6 in human vascular smooth muscle cells resulted in increased [vehicle 156.9 ± 15.8 vs. 1-oleoyl-2-acetyl-sn-glycerol 179.1 ± 8.07 (103 pixels), P = 0.01] or decreased migratory capacity [vehicle 130.0 ± 26.1 vs. SAR7334 111.4 ± 38.0 (103 pixels), P = 0.04], respectively. In a cohort of individuals with angiographic follow-up (n = 3068, males: 69.9%, age: 59 ± 11 years, follow-up 217.1 ± 156.4 days), homozygous carriers of a common genetic variant associated with elevated TRPC6 expression were at increased risk of restenosis after coronary stenting (adjusted odds ratio 1.49, 95% confidence interval 1.08–2.05; P = 0.01). Conclusions Our study provides a proteomic atlas of the healthy and injured arterial wall that can be used to define novel factors for therapeutic targeting. We present TRPC6 as an actionable target to prevent neointima formation secondary to vascular injury and stent implantation.

Original languageEnglish
JournalEuropean Heart Journal
Issue number18
Pages (from-to)1773-1785
Number of pages13
Publication statusPublished - 07.05.2021


Dive into the research topics of 'A proteomic atlas of the neointima identifies novel druggable targets for preventive therapy'. Together they form a unique fingerprint.

Cite this